The Sponsor Consensus: How Trial Sponsors Are Thinking About Real-Time Clinical Trials

The FDA's Real-Time Clinical Trials (RTCT) initiative aims to shift trial oversight from retrospective, episodic reporting to continuous, real-time review, an effort to compress development timelines as competitive pressure from faster-moving markets intensifies. To understand how the industry is actually responding, this report analyzes all 20 sponsor comments filed to FDA's public docket, spanning large pharma, mid-cap and specialty biopharma, emerging biotech, and AI-native developers. Every sponsor supports the shift, but their filings reveal a shared framework for making it trustworthy. The analysis also maps where sponsors say the greatest efficiency gains lie and where real-time review offers less value, such as small, closely monitored first-in-human studies.

For sponsors trying to determine whether and how to prepare for real-time oversight, this report translates a fragmented public record into a practical readiness picture: what trust requires, where the economic case is strongest, and which open questions will shape upcoming guidance. Read on to identify where your own trial portfolio stands to gain the most, and what data and governance practices are worth building now.